Several targeted agents have recently been approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and their use in patients with early- and/or late-stage disease has led to substantial improvements in disease control and overall survival. Nonetheless, an urgent need remains for HER2-targeted regimens capable of overcoming resistance to available therapeutic options and further improving outcomes, and several novel agents are approved or in development. As therapeutic decisions become more complex, oncology/hematology APPs need information on incorporation of molecular markers and novel agents into practice, as well as education on the identification and management of toxicities of these novel agents and combinations. In this video lecture, a breast cancer expert provides advice on predictive biomarkers and how to apply them to guide optimal use of targeted therapies in the care of patients with HER2-positive breast cancer, and reviews the adverse events associated with this diverse set of therapies and their management.
Interactive video lecture
After completing this activity, participants should be better able to:
- Analyze current safety and efficacy data for new targeted therapies for HER2-positive advanced breast cancer
- Design optimized treatment approaches for individual patients with HER2-positive advanced breast cancer
- Implement evidence-based strategies for anticipating, evaluating, and treating adverse events observed with targeted therapies
Oncology NPs, PAs, and nurses
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
NP course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 16, 2022. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was cosupported by educational grants from Astellas and Pﬁzer; AstraZeneca; Bristol Myers Squibb; Dendreon Pharmaceuticals LLC; Eisai; Epizyme Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncopeptides; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Regeneron Pharmaceuticals, Inc. and Sanoﬁ Genzyme; and Seagen Inc. formerly Seattle Genetics.
This activity is supported by an educational grant from Seagen Inc. formerly Seattle Genetics.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose to the audience all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Tolaney: consulting: Athenex Oncology, Certara, Daiichi Sankyo, Kyowa Kirin Pharmaceuticals, Mersana Therapeutics, OncoPep, Puma Biotechnology, Samsung Bioepis, Seagen; consulting/PI: AstraZeneca, Bristol Myers Squibb, Eisai, Genentech/Roche, Immunomedics/Gilead, Lilly, Merck, Nanostring, Nektar, Novartis, Odonate Therapeutics, Pfizer, Sanofi; PI: Cyclacel Pharmaceuticals, Exelixis; steering committee: CytomX Therapeutics.
Ms Sandy: speakers bureau: AstraZeneca, Jazz, Merck, Takeda.
Ms Williams: consulting/speakers bureau: AbbVie, AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- View the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 67%.
The estimated time to complete this activity is 1.00 hour.
Release date: August 17, 2021
Expiration date: August 16, 2022
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 100621O-7C